Выявление факторов, препятствующих успешной HER-таргетной терапии при раке молочной железы и разработка противоопухолевого препарата, связывающего HER-лиганды
6 Января 2018 года 31 Декабря 2020 года
Список публикаций по проекту
- (2020). Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels. Biochemistry (Mosc) 85 (7), 758–772
- (2020). RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens. Biomedicines 8 (5),
- (книга) (2019). RetroSpect, a new method of measuring gene regulatory evolution rates using co-mapping of genomic functional features with transposable elements. Evolution, Origin of Life, Concepts and Methods 42 (1), 85–111
- (2020). Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments. BMC Med Genomics 13 (Suppl 8), 111
- (2020). RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud 6 (2),
- (2021). Editorial: Next Generation Sequencing Based Diagnostic Approaches in Clinical Oncology. Front Oncol 10, 635555
- (2021). Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth. Heliyon 7 (3), e06394
- (2021). EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers. Biochemistry (Mosc) 86 (11), 1477–1488
- (2022). Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem 298 (8), 102226
- (2022). Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. Biomedicines 10 (8),